John Babich from Ratio Therapeutics explains how radiopharmaceuticals can be designed to better treat cancer, alone and in combination with immunotherapies.
Attacking Cancer Targets with Radiotherapeutics
Attacking Cancer Targets with Radiotherapeutics
John Babich from Ratio Therapeutics explains how radiopharmaceuticals can be designed to better treat cancer, alone and in combination with immunotherapies.
John Babich from Ratio Therapeutics explains how radiopharmaceuticals can be designed to better treat cancer, alone and in combination with immunotherapies.
Charlene Lancaster, PhD | Dec 31, 2024 | 4 min read
Ke Hou generated a compound that prevents tau aggregation in the murine brain, but the potential Alzheimer’s disease therapy also had a surprising property.
The Scientist and Sino Biological | Dec 26, 2024 | 3 min read
As kinase dysfunction underlies many pathological conditions, scientists require high-quality active kinases for their therapeutic development programs.
Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseases